HUTCHMED (China) Limited Sponsored ADR (HCM)
(Real Time Quote from BATS)
$16.74 USD
-0.11 (-0.65%)
Updated Jul 10, 2024 10:30 AM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
HCM 16.74 -0.11(-0.65%)
Will HCM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for HCM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HCM
HUTCHMED (HCM) Upgraded to Buy: Here's What You Should Know
Does HUTCHMED (HCM) Have the Potential to Rally 38.13% as Wall Street Analysts Expect?
HCM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 75.05% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?
After Plunging -10.7% in 4 Weeks, Here's Why the Trend Might Reverse for HUTCHMED (HCM)
Wall Street Analysts See a 107.24% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?
Other News for HCM
UK earnings, trading statements calendar - next 21 days
IN BRIEF: Hutchmed's tazemetostat given priority review in China
HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status
HUTCHMED Breaks Below 200-Day Moving Average - Notable for HCM
HUTCHMED Files New SEC Registration Statement